TFS Capital’s Regenxbio RGNX Stock Holding History

TFS Capital’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-51,877	Closed	-$415K	–	938
2016 Q2	$415K	Buy	+51,877	New	+$576K	0.08%	430

Other funds holding RGNX

BCPEM

Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

TFS Capital's RGNX Position: Q3 2016 in Review

TFS Capital sold out of Regenxbio (RGNX) in Q3 2016, closing a stake of 51,877 shares — an estimated $415K sold.

TFS Capital first reported a position in RGNX in Q2 2016 and held it in 1 quarter. The position peaked at $415K in Q2 2016. 71 funds tracked by Wall St. Rank hold RGNX as of Q3 2016.

TFS Capital reported no remaining Regenxbio position as of Q3 2016 after selling out during the quarter.
TFS Capital sold 51,877 Regenxbio shares in Q3 2016, an estimated $415K.
TFS Capital first reported a position in Regenxbio in Q2 2016 and held it in 1 quarter.
TFS Capital's Regenxbio position peaked at $415K in Q2 2016.
71 funds tracked by Wall St. Rank held Regenxbio as of Q3 2016.

Based on TFS Capital's 13F filing for Q3 2016, filed 10 Nov 2016.